Piper Sandler analyst Jason Bednar raised the firm’s price target on Becton Dickinson to $260 from $245 and keeps a Neutral rating on the shares post the fiscal Q1 results. The company posted a solid performance to start fiscal 2023 its outlook for the year that suggests management’s strategy is going to plan, the analyst tells investors in a research note. However, with the shares already trading above historical averages, Piper sees better near-term opportunities elsewhere for medtech investors.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BDX: